HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Exendin-4, an analogue of glucagon-like peptide-1, attenuates hyperalgesia through serotonergic pathways in rats with neonatal colonic sensitivity.

Abstract
Glucagon-like peptide-1 (GLP-1) analogue ROSE-010 can provide effective pain relief from irritable bowel syndrome (IBS). However, the underlying biological mechanism is still unknown. Here, we investigate the effect of GLP-1 analogue exendin-4 on visceral hypersensitivity in colonic sensitized rats. Rat models of visceral hypersensitivity were established by intra-colonic infusion of acetic acid in 10-day-old Sprague-Dawley rats. Visceral sensitivity was assessed by measurement of abdominal withdrawal reflex (AWR) and electromyography (EMG). Exendin-4 with doses of 1, 5, and 10 μg/kg were intraperitoneally administered, respectively. The expressions of serotonin transporter (SERT) and tryptophan hydroxylase-1 (TPH-1) in colonic tissues were detected by RT-PCR and Western blot, respectively. The levels of serotonin (5-HT) and GLP-1 were measured by ELISA assay. Visceral hypersensitivity after neonatal colonic sensitization was verified. The colonic sensitized rats showed low levels of GLP-1 in plasma and high levels of 5-HT in plasma and colonic tissue (P<0.05). Exendin-4 dose-dependently reduced visceral hypersensitivity in colonic sensitized rats. The AWR scores in colonic sensitized rats with exendin-4 (5 μg/kg) reduced to 1.56±0.53 (P=0.013 vs. 2.33±0.50), 2.23±0.45 (P=0.008 vs. 3.0±0.5) during CRD at 40, and 60 mmHg, respectively. Similar findings were showed at dose of 10 μg/kg. Exendin-4 (5 μg/kg and 10 μg/kg) reduced the EMG during CRD at 40, 60, 80 mmHg (P<0.01). Exendin-4 (5.0 μg/kg or 10.0 μg/kg) significantly decreased the 5-HT colonic levels (2.343±0.447, 2.175±0.360 ng/100 mg vs. 3.607±0.628 ng/100 mg, P<0.05). The SERT protein expressions in colonic tissues in colonic sensitized rats were significantly increased with exendin-4 at doses of 1, 5 or 10 μg/kg (0.759±0.068, 0.942±0.037, 0.944±0.097 vs. 0.552±0.047, P<0.05, respectively), and the SERT mRNA expression also increased after treatment with exendin-4. The colonic sensitized rats showed lower TPH-1 levels after treatment with exendin-4 (P<0.05). These findings suggest that exendin-4 reduce visceral hypersensitivity and this may be associated with up-regulating SERT expression, and down-regulating TPH-1 expression.
AuthorsY Yang, X Cui, Y Chen, Y Wang, X Li, L Lin, H Zhang
JournalJournal of physiology and pharmacology : an official journal of the Polish Physiological Society (J Physiol Pharmacol) Vol. 65 Issue 3 Pg. 349-57 (Jun 2014) ISSN: 1899-1505 [Electronic] Poland
PMID24930506 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Peptides
  • Venoms
  • Serotonin
  • Exenatide
  • Acetic Acid
Topics
  • Acetic Acid (administration & dosage, pharmacology)
  • Animals
  • Colon (drug effects, metabolism, pathology)
  • Exenatide
  • Hyperalgesia (drug therapy, metabolism)
  • Male
  • Peptides (blood, pharmacology, therapeutic use)
  • Rats
  • Rats, Sprague-Dawley
  • Serotonin (metabolism)
  • Venoms (blood, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: